NCT00369577View on ClinicalTrials.gov

Staccato Loxapine in Agitation (Proof of Concept)

PHASE2CompletedINTERVENTIONAL
Enrollment

129

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

January 31, 2007

Study Completion Date

January 31, 2007

Conditions
Schizophrenia
Interventions
DRUG

Inhaled Placebo

Inhaled Placebo, single dose

DRUG

Inhaled Loxapine 5 mg

Inhaled Staccato Loxapine 5 mg, single dose

DRUG

Inhaled Loxapine 10 mg

Inhaled Staccato Loxapine 10 mg, single dose

Trial Locations (1)

91786

Pacific Clinical Research Medical Group, 1317 West Foothill Blvd, Suite 200,, Upland

Sponsors
All Listed Sponsors
lead

Alexza Pharmaceuticals, Inc.

INDUSTRY

NCT00369577 - Staccato Loxapine in Agitation (Proof of Concept) | Biotech Hunter | Biotech Hunter